NZ329979A - Use of NK3 receptor antagonists - Google Patents

Use of NK3 receptor antagonists

Info

Publication number
NZ329979A
NZ329979A NZ329979A NZ32997995A NZ329979A NZ 329979 A NZ329979 A NZ 329979A NZ 329979 A NZ329979 A NZ 329979A NZ 32997995 A NZ32997995 A NZ 32997995A NZ 329979 A NZ329979 A NZ 329979A
Authority
NZ
New Zealand
Prior art keywords
disorders
receptor antagonists
epilepsy
psoriasis
medicament
Prior art date
Application number
NZ329979A
Inventor
Carlo Farina
Giuseppe Arnaldo Mari Giardina
Mario Grugni
Luca Francesco Raveglia
Original Assignee
Smithkline Beecham S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT94MI001099A external-priority patent/ITMI941099A1/en
Priority claimed from ITMI950494 external-priority patent/IT1293558B1/en
Application filed by Smithkline Beecham S filed Critical Smithkline Beecham S
Priority claimed from NZ287442A external-priority patent/NZ287442A/en
Publication of NZ329979A publication Critical patent/NZ329979A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Use of an NK3 receptor antagonist in the manufacture of a medicament for treating convulsive disorders, epilepsy, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders, allergic rhinitis, neurodegenerative disorders, psoriasis, Huntingtons disease and depression.
NZ329979A 1994-05-27 1995-05-23 Use of NK3 receptor antagonists NZ329979A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT94MI001099A ITMI941099A1 (en) 1994-05-27 1994-05-27 KINOLINIC DERIVATIVES
ITMI950494 IT1293558B1 (en) 1995-03-14 1995-03-14 New tachykinin receptor antagonising quinoline derivs. - used for treating pulmonary disorders, CNS disorders, skin disorders, neurogenic inflammation, epilepsy and inflammatory pain,etc.
NZ287442A NZ287442A (en) 1994-05-27 1995-05-23 4-substituted quinoline derivatives; medicaments; use as an nk3 receptor antagonist

Publications (1)

Publication Number Publication Date
NZ329979A true NZ329979A (en) 2000-07-28

Family

ID=27274035

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ329979A NZ329979A (en) 1994-05-27 1995-05-23 Use of NK3 receptor antagonists

Country Status (1)

Country Link
NZ (1) NZ329979A (en)

Similar Documents

Publication Publication Date Title
EE9700267A (en) Use of α1L-agonists for the treatment of urinary incontinence
PT901374E (en) TETRA-HYDROPTERIDINS AND PYRIDYLPIPERAZINES FOR THE TREATMENT OF NEUROLOGICAL DISTURBLES
IL115733A (en) Binding agents to cd23 and their use in the manufacture of a medicament
ATE311371T1 (en) NON-PEPTIDE INHIBITORS OF VLA-4 DEPENDENT CELL BINDING FOR THE TREATMENT OF INFLAMMATION, AUTOIMMUNE DISEASES AND RESPIRATORY DISORDERS
DK84193A (en) Vaginal autosuture instrument for the prevention of urinary incontinence in women
ZA200001593B (en) Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz [B,E] oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization.
NO975128D0 (en) Endothelin antagonists and endothelin synthase inhibitors for the prevention and treatment of uterine contraction disorders, preeclampsia, atherosclerotic vascular disease, hypertension and for hormone replacement therapy
NZ334063A (en) use of a combination of a histamine H1 receptor antagonist and a histamine H3 receptor antagonist to treat upper airway allergic responses
PL352229A1 (en) Prosthesis of sclera for treatment of presbyopia and other sight disorders
HU9602449D0 (en) Treatment of obsessive-compulsive disorders with 5-ht2 antagonists
NO994165D0 (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness
DK0501705T3 (en) Use of tomoxetine for the treatment of diseases of the lower urinary tract
AU682166B2 (en) Synergising association having an antagonist effect on NK1 and NK2 receptors
ATE260278T1 (en) 5HT1 RECEPTOR ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF DEPRESSION
NZ329979A (en) Use of NK3 receptor antagonists
IL162482A (en) Use of il6-r/il-6 chimera in the manufacture of a medicament for treatment of neuron loss
AU9157698A (en) Piperazine derivatives active on the lower urinary tract
HK1047549A1 (en) Il6ril6 chimera for the treatment of neurodegeneraive diseases.
AU4856600A (en) Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder
BR9811559A (en) Tricyclic vasopressin agonists
HK1047695A1 (en) Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina
PT1135134E (en) USE OF NEUROTROPHIC FACTOR STIMULATORS FOR THE TREATMENT OF NEURODEGENERATIVE OPHTHALMIC DISEASES
AU5659798A (en) Therapeutic composition comprising the kal protein and use of the kal protein for the treatment of retinal, renal, neuronal and neural injury
ATE222768T1 (en) CTLA-8 IN COMBINATION WITH G-CSF OR WITH G-CSF AND IL-6, AND USE OF CTLA-8 TO TREAT INFECTIONS
EP0797995A3 (en) Use of a 5-HT2 receptor antagonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired